- Home
- JPC vs HCM Comparison
JPC vs HCM Comparison
Compare JPC & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- HCM
- Stock Information
- Founded
- JPC 2003
- HCM 2000
- Country
- JPC United States
- HCM Hong Kong
- Employees
- JPC N/A
- HCM N/A
- Industry
- JPC Investment Managers
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- HCM Health Care
- Exchange
- JPC Nasdaq
- HCM Nasdaq
- Market Cap
- JPC 2.5B
- HCM 2.5B
- IPO Year
- JPC N/A
- HCM N/A
- Fundamental
- Price
- JPC $8.08
- HCM $17.27
- Analyst Decision
- JPC
- HCM Buy
- Analyst Count
- JPC 0
- HCM 2
- Target Price
- JPC N/A
- HCM $23.50
- AVG Volume (30 Days)
- JPC 998.5K
- HCM 42.1K
- Earning Date
- JPC 01-01-0001
- HCM 08-07-2025
- Dividend Yield
- JPC 7.57%
- HCM N/A
- EPS Growth
- JPC N/A
- HCM N/A
- EPS
- JPC N/A
- HCM 0.04
- Revenue
- JPC N/A
- HCM $630,201,000.00
- Revenue This Year
- JPC N/A
- HCM $15.00
- Revenue Next Year
- JPC N/A
- HCM $19.91
- P/E Ratio
- JPC N/A
- HCM $79.28
- Revenue Growth
- JPC N/A
- HCM N/A
- 52 Week Low
- JPC $5.94
- HCM $11.51
- 52 Week High
- JPC $7.36
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- JPC 56.12
- HCM 52.60
- Support Level
- JPC $8.03
- HCM $17.36
- Resistance Level
- JPC $8.18
- HCM $19.50
- Average True Range (ATR)
- JPC 0.04
- HCM 0.42
- MACD
- JPC -0.01
- HCM -0.02
- Stochastic Oscillator
- JPC 80.77
- HCM 30.62
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.